Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from the Phase 3 MARIPOSA study, evaluating rybrevant plus lazcluze as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer, or NSCLC, with epidermal growth factor receptor – EGFR – exon 19 deletions or L858R substitution mutations. The chemotherapy-free combination regimen met the final pre-specified secondary endpoint of OS and demonstrated clinically meaningful and statistically significant improvement in OS versus the current standard of care osimertinib. Improvement in median OS is expected to exceed one year. The safety profile of rybrevant plus lazcluze was generally consistent with the profiles of the individual treatments. Adverse event rates were consistent in this arm as compared to other rybrevant regimens. These OS results will be presented at an upcoming major medical meeting, and will be shared with global health authorities. Rybrevant with lazcluze is approved in the U.S. and Europe for the first-line treatment of patients with EGFR-mutated NSCLC based on the MARIPOSA Phase 3 study.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- RBC downgrades Neumora Therapeutics to Sector Perform after trial failure
- Neumora trial failure a ‘big blow’ to bull case, says Stifel
- Piper lowers sales estimates for Legend Biotech’s Carvykti
- Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal
- Johnson & Johnson licensing STAT6 program from Kaken Pharmaceutical
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
